Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37.52 | 39.98 | 40.22 | 39.18 | 41.22 | 43.83 | 44.97 | 45.20 | 45.80 | 37.75 | 58.45 | 48.71 |
| Expenses | 32.40 | 35.26 | 36.11 | 34.81 | 36.72 | 39.56 | 40.58 | 44.88 | 46.69 | 40.07 | 57.12 | 47.59 |
| Operating Profit | 5.12 | 4.72 | 4.11 | 4.37 | 4.50 | 4.27 | 4.39 | 0.32 | -0.89 | -2.32 | 1.33 | 1.12 |
| OPM % | 13.65% | 11.81% | 10.22% | 11.15% | 10.92% | 9.74% | 9.76% | 0.71% | -1.94% | -6.15% | 2.28% | 2.30% |
| Other Income | 0.35 | 0.50 | 0.92 | 0.18 | 0.11 | 0.11 | 0.30 | 0.36 | 0.16 | 0.45 | 0.76 | 2.35 |
| Interest | 1.16 | 1.24 | 1.40 | 1.49 | 1.65 | 1.54 | 1.64 | 2.53 | 2.68 | 2.85 | 2.89 | 4.97 |
| Depreciation | 2.17 | 2.19 | 2.20 | 2.28 | 2.35 | 2.33 | 2.16 | 4.21 | 4.29 | 4.36 | 4.28 | 4.33 |
| Profit before tax | 2.14 | 1.79 | 1.43 | 0.78 | 0.61 | 0.51 | 0.89 | -6.06 | -7.70 | -9.08 | -5.08 | -5.83 |
| Tax % | 27.10% | 32.96% | 32.17% | 21.79% | 201.64% | 78.43% | 41.57% | -8.09% | -9.09% | -21.70% | -1.97% | -1.54% |
| Net Profit | 1.56 | 1.21 | 0.97 | 0.60 | -0.61 | 0.11 | 0.52 | -5.58 | -6.99 | -7.12 | -4.98 | -5.75 |
| EPS in Rs | 1.68 | 1.30 | 1.04 | 0.64 | -0.60 | 0.11 | 0.35 | -5.40 | -6.76 | -4.77 | -3.32 | -3.82 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 60 | 62 | 80 | 135 | 170 | 155 | 169 | 187 | 191 |
| Expenses | 49 | 55 | 56 | 68 | 110 | 135 | 135 | 151 | 188 | 191 |
| Operating Profit | 6 | 5 | 5 | 11 | 26 | 35 | 20 | 18 | -1 | -1 |
| OPM % | 10% | 8% | 9% | 14% | 19% | 21% | 13% | 10% | -0.5% | -0.4% |
| Other Income | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 2 | 4 |
| Interest | 0 | 1 | 1 | 1 | 2 | 4 | 5 | 7 | 12 | 13 |
| Depreciation | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 9 | 17 | 17 |
| Profit before tax | 2 | 2 | 1 | 9 | 19 | 25 | 8 | 3 | -28 | -28 |
| Tax % | 34% | 7% | 38% | 24% | 28% | 26% | 31% | 78% | -12% | |
| Net Profit | 1 | 2 | 1 | 7 | 14 | 18 | 6 | 1 | -25 | -25 |
| EPS in Rs | 1.19 | 2.06 | 0.92 | 7.43 | 14.96 | 20.02 | 5.95 | 0.42 | -16.44 | -18.67 |
| Dividend Payout % | 56% | 32% | 43% | 9% | 5% | 5% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 19% | 3% | 9% | ||
| Compounded Profit Growth | % | % | % | -238% | ||
| Stock Price CAGR | 9% | 4% | -25% | -41% | ||
| Return on Equity | % | 3% | -2% | -9% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 7 | 9 | 9 | 10 | 10 |
| Reserves | 48 | 49 | 49 | 56 | 76 | 114 | 194 | 176 | 165 |
| Borrowings | 0 | 5 | 6 | 10 | 53 | 97 | 109 | 152 | 162 |
| Other Liabilities | 19 | 14 | 14 | 27 | 29 | 70 | 64 | 81 | 87 |
| Total Liabilities | 73 | 75 | 76 | 99 | 165 | 290 | 377 | 419 | 424 |
| Fixed Assets | 22 | 24 | 24 | 38 | 66 | 97 | 103 | 284 | 274 |
| CWIP | 1 | 2 | 2 | 7 | 20 | 88 | 144 | 0 | 4 |
| Investments | 5 | 5 | 6 | 0 | 0 | 0 | 3 | 3 | 3 |
| Other Assets | 45 | 43 | 45 | 54 | 79 | 105 | 127 | 133 | 143 |
| Total Assets | 73 | 75 | 76 | 99 | 165 | 290 | 377 | 419 | 424 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 5 | 2 | 7 | 13 | -1 | 17 | -8 | 27 | 11 |
| Cash from Investing Activity | -1 | -7 | -6 | -16 | -46 | -105 | -73 | -44 | -11 |
| Cash from Financing Activity | -4 | 4 | -1 | 3 | 48 | 87 | 82 | 16 | -1 |
| Net Cash Flow | 0 | -1 | 0 | -0 | 1 | 0 | 1 | -2 | -0 |
| Free Cash Flow | 4 | -5 | 2 | -11 | -47 | -88 | -79 | -18 | -1 |
| CFO/OP | 97% | 57% | 144% | 134% | 17% | 64% | -32% | 162% | -1,634% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 208 | 197 | 180 | 123 | 71 | 112 | 128 | 134 | 139 |
| Inventory Days | 149 | 87 | 89 | 82 | 34 | 45 | 88 | 109 | 94 |
| Days Payable | 185 | 114 | 91 | 159 | 98 | 127 | 141 | 166 | 197 |
| Cash Conversion Cycle | 172 | 170 | 179 | 45 | 7 | 30 | 75 | 78 | 36 |
| Working Capital Days | 186 | 143 | 121 | 35 | 73 | 61 | 80 | 53 | -1 |
| ROCE % | 5% | 4% | 11% | 21% | 15% | 5% | 3% | -5% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 56.57% | 56.57% | 56.57% | 56.57% | 51.59% | 51.13% | 51.21% | 51.26% | 51.26% | 51.26% | 51.04% | 50.92% |
| DIIs | 1.31% | 1.31% | 1.31% | 0.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 42.13% | 42.13% | 42.13% | 43.25% | 48.39% | 48.86% | 48.80% | 48.75% | 48.73% | 48.74% | 48.96% | 49.09% |
| No. of Shareholders | 11,675 | 11,399 | 10,954 | 10,514 | 9,862 | 9,661 | 9,425 | 9,311 | 9,573 | 9,075 | 8,850 | 8,756 |
Fundamentals
Market Cap₹ 170 Cr.
Current Price₹ 165
Book Value₹ 168
ROCE-4.58 %
ROE-9.45 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)9%
Compounded Profit Growth (TTM)-238%
Consolidated figures.
Valuation
Market capRs 168 Cr
Enterprise valueRs 314 Cr
Price to book0.90x
Price to sales0.88x
EV / EBITDA106.18x
EV / sales1.65x
Price to cash flow6.27x
Earnings yield-11.54%
P/E, 3-year average171.41x
P/B, 3-year average1.79x
P/E, 5-year average108.62x
P/B, 5-year average1.95x
Profitability
Operating margin (excl. other income)10.50%
Operating margin (incl. other income)10.92%
EBITDA margin1.55%
Pre-tax margin-14.52%
Net profit margin-10.15%
Net margin, latest quarter-8.17%
ROE0.22%
ROCE2.87%
ROA0.11%
ROE, 3-year average7.17%
ROCE, 3-year average8.00%
ROA, 3-year average3.30%
ROE, 5-year average10.49%
ROCE, 5-year average11.84%
ROA, 5-year average5.66%
ROIC (approx.)-0.94%
Tax rate78.14%
Other income / net worth0.38%
Growth
Sales growth (latest year)8.98%
Profit growth (latest year)-92.25%
Sales CAGR, 3 years7.75%
Sales CAGR, 5 years22.38%
Profit CAGR, 3 years-68.62%
Profit CAGR, 5 years-12.94%
Sales growth QoQ-16.66%
Sales growth YoY (latest quarter)7.77%
Per share
EPS (TTM)Rs -18.71
EPS (latest year)Rs 0.42
EPS (latest quarter)Rs -3.85
EPS, 3-year averageRs 8.74
EPS, 5-year averageRs 11.88
Book value per shareRs 180.12
Sales per shareRs 184.42
Cash flow per shareRs 25.87
Free cash flow per shareRs -0.97
Dividend per share, 3-year averageRs 1.00
Dividend per share, 5-year averageRs 1.04
Dividends
Dividend payout, 3-year average5.04%
Dividend payout, 5-year average6.35%
Efficiency
Asset turnover0.40x
Fixed asset turnover0.60x
Inventory turnover4.50x
Inventory days81 days
Debtor days134 days
Debtors turnover2.71x
Creditor days197 days
Cash conversion cycle36 days
Working capital days-1 days
Leverage
Total debtRs 152 Cr
Cash and bankRs 5 Cr
Net debtRs 147 Cr
Debt to equity0.82x
Net debt / EBITDA49.52x
Interest coverage-1.07x
Owners' fund to total sources44.42%
Debt to assets36.22%
Cash flow
Cash from Operating Activity (latest year)Rs 27 Cr
Cash from Investing Activity (latest year)Rs -44 Cr
Cash from Financing Activity (latest year)Rs 16 Cr
Net Cash Flow (latest year)Rs -2 Cr
Free cash flow (latest year)Rs -1 Cr
FCFE (approx.: FCF + change in debt)Rs 42 Cr
Cash from ops / profit, 5 years3.29x
Sales to cash flow6.32x
Statement figures
Net sales (TTM)Rs 191 Cr
Net sales (latest year)Rs 169 Cr
Sales (latest quarter)Rs 49 Cr
Operating profit excl. other income (latest year)Rs 18 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 4 Cr
EBITDA (TTM)Rs 3 Cr
PBDT (TTM)Rs -10 Cr
Profit before tax (TTM)Rs -28 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs -19 Cr
Net profit (latest year)Rs 0 Cr
Net profit (latest quarter)Rs -4 Cr
Depreciation (TTM)Rs 17 Cr
Depreciation (latest quarter)Rs 4 Cr
Interest (TTM)Rs 13 Cr
Cost of goods sold (latest year)Rs 115 Cr
Total expenditure (latest year)Rs 151 Cr
Total income (latest year)Rs 170 Cr
Share capitalRs 10 Cr
ReservesRs 176 Cr
Shareholders' fundsRs 186 Cr
Total assetsRs 419 Cr
Net blockRs 284 Cr
InvestmentsRs 3 Cr
ReceivablesRs 62 Cr
InventoryRs 25 Cr
Other liabilitiesRs 81 Cr
Shares outstanding (crore)1.03
Ownership
Promoter holding50.92% (-0.34 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 0.90 is at the 24th percentile (median 2.26).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | NATCAPSUQ | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -4.0% | -2.8% | -1.2 pts |
| 1 month | -19.5% | -6.8% | -12.7 pts |
| 3 months | +6.4% | -7.6% | +14.0 pts |
| 6 months | +12.3% | +0.4% | +11.9 pts |
| 1 year | -37.6% | -9.9% | -27.7 pts |
| 3 years | -57.6% | +14.2% | -71.8 pts |
| 5 years | +24.2% | +27.9% | -3.7 pts |
Red flags
F-score 3 of 8| explain | Debt up, profit down Borrowings up 39% while net profit fell in 2026 |
| explain | Low interest cover Interest cover 1.4x in 2026 |
| look | Share dilution Share count up 11% in a year, 11% in three |
| look | Regulator order or action Regulator order or action 2026-01-30: Natural Capsules Limited has informed the Exchange about Action(s) taken or orders passed |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹49 Cr +7.8% vs Jun 2025.
Net loss ₹6 Cr.
Against our estimate for Jun 2026: sales -0.3%, profit +14.7% in line. Our estimate for Sep 2026: sales Rs 54 Cr, profit Rs -7 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of Natural Capsules Ltd?
Natural Capsules Ltd (NATCAPSUQ) has a market capitalisation of Rs 170 Cr. at the 2026-10-01 close.
What were Natural Capsules Ltd's latest quarterly results?
In the Jun 2026 quarter, Natural Capsules Ltd sales was Rs 49 Cr (+7.8% vs Jun 2025) with a net loss of Rs 6 Cr.
What is the 52-week high and low of Natural Capsules Ltd?
The 52-week high is Rs 290.99 and the 52-week low is Rs 136.36.